scholarly journals A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials

2020 ◽  
Vol 9 (7) ◽  
pp. 2253
Author(s):  
Theresa Steeb ◽  
Anja Wessely ◽  
Matthias Harlaß ◽  
Franz Heppt ◽  
Elias A. T. Koch ◽  
...  
Keyword(s):  
Actinic Keratosis ◽  
Meta Analysis ◽  
Diclofenac Sodium ◽  
Total Sample ◽  
Random Effects Model ◽  
Ingenol Mebutate ◽  
Surveillance Studies ◽  
Relative Risks ◽  
Post Marketing Surveillance ◽  
Post Marketing

Multiple interventions are available for the treatment of actinic keratosis (AK) showing high efficacy in pivotal trials. However, data from post-marketing surveillance studies have received little attention until now. Here, we systematically investigate interventions for AK from post-marketing surveillance trials as a proxy for real-world efficacy and tolerability. A systematic literature search was conducted in Medline, Embase, and CENTRAL. Pertinent trial registers were hand-searched until 25 March 2020. Results were pooled using a random-effects model to calculate pooled proportions and relative risks (RR) or were described qualitatively. Eleven records with a total sample size of n = 4109 were included. Three of the studies had an active-controlled design, while seven were single-armed. Participant complete clearance ranged from 23.1% for diclofenac sodium 3% gel to 88.9% for ingenol mebutate 0.05% gel. The lesion-specific clearance rate for photodynamic therapy (PDT) was 74% (95% confidence interval (CI) 56–87%). The recurrence rate was significantly higher for diclofenac sodium 3% in comparison to imiquimod 5% cream (RR 1.10, 95% CI 1.02–1.1.8) and ranged from 10.6% for ingenol mebutate 0.015% gel to 23.5% for PDT. Few patients discontinued the trials due to adverse events. The results from the majority of the post-marketing surveillance studies deviated from those of pivotal trials.

scholarly journals Legume Consumption and All-Cause and Cardiovascular Disease Mortality

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Hua Li ◽  
Jinmeng Li ◽  
Yegen Shen ◽  
Jie Wang ◽  
Depu Zhou
Keyword(s):  
Cardiovascular Disease ◽  
Lower Risk ◽  
Meta Analysis ◽  
Random Effects Model ◽  
Protective Effects ◽  
Prospective Cohort Studies ◽  
Relative Risks ◽  
Disease Mortality ◽  
All Cause Mortality ◽  
Cvd Mortality

Background. Legume consumption is suggested to have protective effects against cardiovascular disease (CVD) mortality in the general population, but the results have been equivocal. We conducted a meta-analysis of prospective cohort studies to assess the association between legume consumption and risk of CVD mortality and all-cause mortality. Methods and Results. Medline (via Ovid) and EMBASE (via Ovid) databases were searched through April 2017 to identify eligible studies. The two authors independently extracted the data and the adjusted relative risks (RRs) and 95% confidence intervals (CIs) were pooled by using a random-effects model. A total of 6 studies were identified, including the sizes of participants ranging from 23,601 to 59,485 with a sum of 21,8997. Comparing the highest category with the lowest, the pooled RR (95% CI) was 0.96 (0.86–1.06) for CVD mortality and 0.93 (0.87–0.99) for all-cause mortality. Conclusions. Results from the current study show that high legume intakes are associated with lower risk of all-cause mortality. In consideration of the small number of studies, the evidence for assessing relationship between legumes intake and risk of all-cause mortality remains inclusive and warrants further study in the future. Further, consuming legumes does not increase the risk of CVD mortality.

Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies

2009 ◽  
Vol 69 (01) ◽  
pp. 70-81 ◽  
Author(s):  
D Sugiyama ◽  
K Nishimura ◽  
K Tamaki ◽  
G Tsuji ◽  
T Nakazawa ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factor ◽  
Observational Studies ◽  
Meta Analysis ◽  
Smoking History ◽  
Random Effects Model ◽  
Relative Risks ◽  
Adjustment Factors ◽  
Participant Characteristics ◽  
Heavy Smokers

Objectives:To assess whether smoking is a risk factor for developing rheumatoid arthritis (RA).Design:Meta-analysis.Method:Data sources were observational studies that examined the association between smoking history and the risk of developing RA identified through Medline and EMBASE (from 1966 to December 2006), relevant books and a reference search. Two authors independently extracted the following: authors’ names, publication year, sample size, participant characteristics, odds ratios (OR) or relative risks, adjustment factors, study design and area where the study was conducted. Data syntheses were based upon random effects model. Summarised syntheses effects were expressed by OR.Results:Sixteen studies were selected from among 433 articles. For men, summary OR for ever, current and past smokers were 1.89 (95% CI 1.56 to 2.28), 1.87 (1.49 to 2.34) and 1.76 (1.33 to 2.31), respectively. For rheumatoid factor-positive (RF+) RA, summary OR for ever, current and past smokers were 3.02 (2.35 to 3.88), 3.91 (2.78 to 5.50) and 2.46 (1.74 to 3.47), respectively. Summary OR for 20 or more pack-years of smoking was 2.31 (1.55 to 3.41). For women, summary OR for ever, current and past smokers were 1.27 (1.12 to 1.44), 1.31 (1.12 to 1.54) and 1.22 (1.06 to 1.40), respectively. For RF+ RA, summary OR for ever, current and past smokers were 1.34 (0.99 to 1.80), 1.29 (0.94 to 1.77) and 1.21 (0.83 to 1.77). Summary OR for 20 or more pack-years of smoking was 1.75 (1.52 to 2.02).Conclusion:Smoking is a risk factor for RA, especially RF+ RA men and heavy smokers.

Sign in / Sign up

Export Citation Format

Share Document